Search 33,000+ CME courses
Back

StatPearls, LLC

  • Diabetes Mellitus, Type 2
  • Diabetic Ketoacidosis
  • Heart Failure
  • Renal Insufficiency, Chronic
  • Sodium-Glucose Transporter 2 Inhibitors

Sodium-Glucose Transport 2 (SGLT2) Inhibitors

Sodium-glucose cotransporter 2 (SGLT2) inhibitors, including canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin, have transformed the management of type 2 diabetes mellitus (T2DM) by providing glucose-lowering efficacy together with cardiovascular and renal protection. Initially approved as adjuncts to diet and exercise for glycemic control, these agents now have expanded indications that include reducing hospitalizations for heart failure, preserving renal function, and lowering cardiovascular mortality in patients with or without diabetes. The mechanism of action of SGLT2 inhibitors involves inhibiting glucose reabsorption within the proximal renal tubules, resulting in glucosuria, modest weight loss, and blood pressure reduction. Evidence demonstrates benefits in heart failure with reduced or preserved ejection fraction and in chronic kidney disease, supporting their incorporation into major international guidelines. Despite substantial clinical advantages, therapy requires attention to safety considerations such as volume depletion, genital infections, diabetic ketoacidosis, and potential lower extremity complications. Optimizing patient outcomes depends on appropriate selection, dosing, monitoring, and interprofessional strategies that enhance adherence and long-term care. This activity for healthcare professionals is designed to enhance learners’ proficiency in integrating SGLT2 therapy into the comprehensive care of patients with T2DM and high cardiovascular or renal risk. Participants will gain deeper insights into the pharmacologic mechanisms, clinical benefits, dosing strategies, safety considerations, and guideline-based monitoring of these drugs. Strengthened skills will equip clinicians to participate in the interprofessional care of patients with T2DM and cardiovascular or renal comorbidities, improving outcomes.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

AAPA Category 1 Credit™Up to 2 creditsAMA PRA Category 1 Credit™Up to 2 creditsNursingUp to 2 creditsPharmacyUp to 2 credits

MOC types

ABS — Accredited CMEUp to 2 pointsABPATH — Lifelong LearningUp to 2 pointsABA — Lifelong LearningUp to 2 pointsABTS — Accredited CMEUp to 2 pointsABIM — Medical KnowledgeUp to 2 pointsABS — Self-AssessmentUp to 2 pointsABP — Lifelong Learning and Self-AssessmentUp to 2 pointsABTS — Self-AssessmentUp to 2 points

FDA REMS

No

Qualifies for MIPS

No

Target Specialties

Cross-Specialty

Relevant across 10 specialties.

Pricing

Fee varies

This provider typically $49–98

See fees on statpearls.com

Listed by the provider

  • Article / monograph / reference
  • Credit · Up to 2 credits
  • MOC · Up to 2 points
  • Fee varies · this provider typically $49–98
  • Released
    Sep 1, 2026
  • Last day to claim credit
    Sep 1, 2029 3 years left

Related courses

See all

Other providers’ courses on the same topic

More from StatPearls, LLC

See all

This provider’s courses closest to this one